USP30-AS1 has emerged as a critical biomarker in colon cancer progression and prognosis, demonstrating significant correlations with aggressive clinicopathological features including larger tumor size, lymph node metastasis, and advanced TNM stage, all indicative of poor clinical outcomes (Yang et al., 2019). This evidence concerns the gene USP30 and malignant colon neoplasm.